Quantum-Si
Stock Watch
Stock Watch will tell you what changes at Quantum-Si.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.702 $ to 2.60 $ · Last price: 1.60 $ (As of: October 2, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/02/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Devices
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Quantum-Si QSI | 0.4 | – | 0.6 | 35.0 | -7,450.3 | -20.3 | -2.1 |
| Abbott Laboratories ABT | 165.9 | 28.4 | 17.6 | 56.9 | 13.5 | 5.7 | -25.0 |
| Medtronic PLC MDT | 109.7 | 24.0 | 13.2 | 65.3 | 22.1 | 8.4 | -6.5 |
| Stryker Corporation SYK | 104.0 | 34.4 | 16.8 | 65.6 | 17.8 | 11.2 | -24.0 |
| Boston Scientific Corp BSX | 61.6 | 18.4 | 13.6 | 69.2 | 20.6 | 19.9 | -55.7 |
| Edwards Lifesciences Corp EW | 49.1 | 46.5 | 28.1 | 77.8 | 31.2 | 11.6 | 11.1 |
| DexCom Inc DXCM | 33.0 | 36.1 | 20.9 | 62.5 | 21.4 | 15.6 | 28.5 |
| GE HealthCare Technologies Inc. GEHC | 27.9 | 15.8 | 10.4 | 39.5 | 11.1 | 4.8 | -16.2 |
| STERIS plc STE | 20.3 | 27.3 | 13.4 | 44.4 | 20.0 | 8.7 | -12.3 |
| Median of companies shown | 49.1 | 27.9 | 13.6 | 62.5 | 20.0 | 8.7 | -12.3 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -37 | -36 | -0.26 | -31 | 35 | 37 |
| 2020 | 0 | -37 | -37 | -6.81 | -33 | 36 | 41 |
| 2021 | 0 | -97 | -95 | -1.19 | -67 | 477 | 503 |
| 2022 | 0 | -124 | -132 | -0.95 | -91 | 359 | 391 |
| 2023 | 1 | -111 | -96 | -0.68 | -94 | 272 | 298 |
| 2024 | 3 | -109 | -101 | -0.71 | -88 | 215 | 248 |
| 2025 | 2 | -97 | -101 | -0.51 | -95 | 220 | 246 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.16 | -6.70 | 1 | 252.90 | -3,216.40 | -23 | -24 |
| 2024: Q4 | -0.16 | -2.20 | 1 | 198.00 | -2,778.60 | -23 | -24 |
| 2025: Q1 | -0.11 | 8.30 | 1 | 84.20 | -2,279.00 | -26 | -28 |
| 2025: Q2 | -0.11 | 26.70 | 1 | -5.00 | -4,879.20 | -20 | -21 |
| 2025: Q3 | -0.17 | -6.30 | 1 | -29.90 | -6,467.90 | -32 | -33 |
| 2025: Q4 | -0.08 | 53.40 | 1 | -62.20 | -3,904.90 | -16 | -16 |
| 2026: Q1 | -0.09 | 18.20 | 0 | -69.40 | -8,399.60 | -26 | -26 |
| 2026: Q2 | -0.11 | 0.00 | 0 | -41.80 | -6,841.30 | -18 | -19 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Breakout & Setup
Research
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Beneish M-Score
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.40 | -0.40 – -0.40 | 1 | -4.7% | 1 |
| 12/31/2027 | -0.35 | -0.35 – -0.35 | 6 | 12.5% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Geprüft am 02.10.2026 gegen die Geschäftsberichte (10-K) 2025 (eingereicht 03.03.2026) und 2024 (03.03.2025) sowie die Quartalsberichte (10-Q) zum 30.06.2026, 31.03.2026, 30.09.2025 und 30.06.2025: Quantum-Si setzt nach eigener Darstellung künstliche Intelligenz und maschinelles Lernen in Forschung und Entwicklung ein — vor allem, um die Modelle zu trainieren, mit denen das Gerät die Signale der einzelnen Aminosäuren deutet — sowie in der Verwaltung; maschinelles Lernen ist zudem Gegenstand eigener Patente. Umsatz macht Quantum-Si aber mit Sequenziergeräten, Verbrauchsmaterial und Service (2025: 2,4 Mio. US-Dollar), nicht mit einem eigenständigen KI-Produkt. Die KI-Passagen im Risikoteil sind allgemeine Regulierungs- und Datenschutz-Klauseln ohne konkrete Bedrohung des Geschäftsmodells. Nach dem Kriterienkatalog daher „nutzt“.
View the full file — quotes, sources, reviewed filings
„Utilizing artificial intelligence, we can continuously train our models and improve the accuracy of the database used to interpret these kinetic signatures, resulting in higher data output and accuracy."
Mithilfe künstlicher Intelligenz können wir unsere Modelle fortlaufend trainieren und die Genauigkeit der Datenbank verbessern, mit der diese kinetischen Signaturen gedeutet werden — das führt zu mehr Daten und höherer Genauigkeit.
10-K · 2026-03-03 · View SEC filing
„We use artificial intelligence, machine learning and automated decision-making technologies (“AI”) to assist in the performance, efficiency, and speed of various functions at the Company, including, but not limited to, general and administrative activities and research and development."
Wir setzen künstliche Intelligenz, maschinelles Lernen und Technologien zur automatisierten Entscheidungsfindung („KI“) ein, um Leistung, Effizienz und Tempo verschiedener Funktionen im Unternehmen zu unterstützen, darunter unter anderem Verwaltungsaufgaben sowie Forschung und Entwicklung.
10-K · 2026-03-03 · View SEC filing
Filings Reviewed: 10-Q 2026-08-13 · 10-Q 2026-05-07 · 10-Q 2025-11-05 · 10-Q 2025-08-05 · 10-K 2026-03-03 · 10-K 2025-03-03
Rated on October 2, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 74.4%
- More than 10% revenue growth is expected for the coming year -53.0%
- Share count grows by less than 3% a year 12.4%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -4,011.9%
- Gross margin at 40% or higher and without meaningful erosion 47.3%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 159 m net cash
- Operating cash flow covers the profits of the last three years 22 m
- Return on capital at 15% or higher, or up versus two years ago -43.7%
- Insiders hold at least 10% or are net buyers 10.5%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 54.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 54.2%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -46.0%
- ROCE > 15% -43.7%
- Expected return > 10% 11.3%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Hawkins Jeffrey Alan | President & CEO | Sell | 9,709 | 0.7608 | 7,387 |
| Sep 22, 2026 | Keyes Jeffry R. | Chief Financial Officer | Sell | 2,493 | 0.7608 | 1,897 |
| Sep 22, 2026 | LaPointe Christian | GC & Corp. Secretary | Sell | 4,721 | 0.7608 | 3,592 |
| Sep 21, 2026 | Hawkins Jeffrey Alan | President & CEO | Sell | 20,143 | 0.7558 | 15,224 |
| Sep 21, 2026 | Keyes Jeffry R. | Chief Financial Officer | Sell | 5,172 | 0.7558 | 3,909 |
| Sep 21, 2026 | LaPointe Christian | GC & Corp. Secretary | Sell | 9,795 | 0.7558 | 7,403 |
| Apr 21, 2026 | Jeffry R Keyes | CFO | Sell | 37,381 | 0.99 | 37,007 |
| Apr 20, 2026 | Jeffrey Alan Hawkins | CEO | Sell | 83,712 | 1.01 | 84,549 |
| Apr 20, 2026 | Jeffry R Keyes | CFO | Sell | 37,382 | 1.01 | 37,756 |
The company
About the Company
Quantum-Si Incorporated aus Branford (Connecticut) entwickelt Geräte zur Proteinsequenzierung auf Einzelmolekül-Ebene: Ein Halbleiterchip misst, wie Eiweiß-Sonden an die Bausteine einzelner Proteinbruchstücke andocken. Verkauft werden die Geräte Platinum und Platinum Pro samt Verbrauchskits und Service; das Nachfolgegerät Proteus soll im zweiten Quartal 2027 auf den Markt kommen. Das 2013 von Jonathan Rothberg gegründete Unternehmen ist seit Juni 2021 an der Nasdaq notiert.
- Employees
- 145
- Headquarters
- Branford, CT
- Address
- 29 Business Park Drive, 06405 Branford, United States
- Phone
- 866 688 7374
- Website
- quantum-si.com
- IPO Date
- 06/10/2021
- ISIN
- US74765K1051
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey Alan Hawkins | President, CEO & Director | 1978 |
| Jonathan M. Rothberg Ph.D. | Founder & Executive Director | 1964 |
| Todd Rearick | Chief Technology Officer | – |
| Christian Lapointe J.D., Ph.D. | General Counsel & Corporate Secretary | 1972 |
| Lindsay Thompson | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 09/29/2026 Quantum-Si Inc (QSI): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/13/2026 Quantum-Si Inc (QSI): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/24/2026 Quantum-Si Inc (QSI): Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SEC ↗
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.